Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
|Videos|March 5, 2021
Dr. Bishoy M. Faltas on the role of genomic testing in bladder cancer
Author(s)Urology Times staff
“The role of genomic testing in bladder is expanding almost every year,” says Faltas.
Advertisement
Bishoy M. Faltas, MD, assistant professor of Medicine at Weill Cornell Medicine, explains the growing role of genomic testing in bladder cancer, including the emerging understanding of the role of germline alterations.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
FDA updates in urology: September 2026
3
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5